Vaxcyte, Inc.
PCVXNASDAQHealthcare● Active
$46.93
$-0.43(-0.92%)
Market Cap$6.8B
P/E Ratio—
52W High$65
52W Low$29.08
Vaxcyte, Inc. (PCVX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PCVX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$2.30
Est. -$1.77 · -29.6%
Revenue
—
Est. $0.01B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS
PCVX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.46
Rev. $3.65B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.46
Rev. Est.$3.65B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$1.99 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$1.77 | -$2.30 | -29.6% | — | $0.01B | — |
| ▼ Q1 FY2026 | Feb 24, 2026 | -$1.53 | -$1.80 | -17.7% | — | $0.02B | — |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$1.27 | -$1.56 | -22.8% | — | — | — |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$1.12 | -$1.22 | -8.9% | — | — | — |
| ▼ Q2 FY2025 | May 7, 2025 | -$1.02 | -$1.04 | -2.0% | — | — | — |
| ▲ Q1 FY2025 | Feb 25, 2025 | -$1.16 | -$1.02 | +12.1% | — | — | — |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$1.10 | -$0.83 | +24.6% | — | — | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$1.99
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$2.30
EPS Est.
-$1.77
EPS Surpr.
-29.6%
Revenue
—
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
-$1.80
EPS Est.
-$1.53
EPS Surpr.
-17.7%
Revenue
—
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$1.56
EPS Est.
-$1.27
EPS Surpr.
-22.8%
Revenue
—
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$1.22
EPS Est.
-$1.12
EPS Surpr.
-8.9%
Revenue
—
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$1.04
EPS Est.
-$1.02
EPS Surpr.
-2.0%
Revenue
—
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
-$1.02
EPS Est.
-$1.16
EPS Surpr.
+12.1%
Revenue
—
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.83
EPS Est.
-$1.10
EPS Surpr.
+24.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.64 | $-0.64 | $-0.64 | 2 |
| Q3 FY2027 | $-0.58 | $-0.58 | $-0.58 | 1 |
| Q2 FY2027 | $-1.43 | $-1.43 | $-1.43 | 1 |
| Q1 FY2027 | $-1.38 | $-1.38 | $-1.38 | 2 |
| Q4 FY2026 | $-2.04 | $-2.04 | $-2.04 | 2 |
| Q3 FY2026 | $-2.06 | $-2.06 | $-2.06 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -29.6% | $55.64 | $57.10 | +2.62% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -17.7% | $60.26 | $61.35 | +1.81% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -22.8% | $42.83 | $41.35 | -3.46% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -8.9% | $33.73 | $33.00 | -2.16% |
| ▼ Q2 FY2025 | May 7, 2025 | -2.0% | $29.24 | $29.00 | -0.82% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +12.1% | $81.68 | $79.35 | -2.85% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +24.6% | $106.49 | $107.56 | +1.00% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -12.8% | $72.74 | $73.93 | +1.64% |
Q2 FY2026+2.62%
Report Date
May 6, 2026
EPS Beat/Miss
-29.6%
Price Before
$55.64
Price After
$57.10
Q1 FY2026+1.81%
Report Date
Feb 24, 2026
EPS Beat/Miss
-17.7%
Price Before
$60.26
Price After
$61.35
Q4 FY2025-3.46%
Report Date
Nov 4, 2025
EPS Beat/Miss
-22.8%
Price Before
$42.83
Price After
$41.35
Q3 FY2025-2.16%
Report Date
Aug 6, 2025
EPS Beat/Miss
-8.9%
Price Before
$33.73
Price After
$33.00
Q2 FY2025-0.82%
Report Date
May 7, 2025
EPS Beat/Miss
-2.0%
Price Before
$29.24
Price After
$29.00
Q1 FY2025-2.85%
Report Date
Feb 25, 2025
EPS Beat/Miss
+12.1%
Price Before
$81.68
Price After
$79.35
Q4 FY2024+1.00%
Report Date
Nov 5, 2024
EPS Beat/Miss
+24.6%
Price Before
$106.49
Price After
$107.56
Q3 FY2024+1.64%
Report Date
Aug 6, 2024
EPS Beat/Miss
-12.8%
Price Before
$72.74
Price After
$73.93
Avg Beat Reaction-0.93%
Avg Miss Reaction-0.06%
Beat Rate2 / 8 quarters
Largest Move-3.46% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PCVX ends December
Vaxcyte, Inc. (PCVX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-2.30 — missing the analyst consensus of $-1.77 by -29.6%. The next PCVX earnings date is expected around September 1, 2026.
Each quarter, investors track PCVX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PCVX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PCVX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PCVX earnings · 5 questionsVaxcyte, Inc.'s next earnings report is expected around September 1, 2026. PCVX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PCVX historically reports after market close (AMC).
PCVX earnings datewhen is PCVX earningsPCVX next earnings datewhen does PCVX report earningsPCVX earnings calendar
▸ Source: FMP · Vaxcyte, Inc. SEC filings · US GAAP · Vaxcyte, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026